Assessment of [(18)F]-fluoroacetate PET/CT as a tumor-imaging modality: preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor.

OBJECTIVE: Although [(18)F]-FDG is a useful oncologic PET tracer, FDG uptake is known to be low in a certain type of hepatocellular carcinoma (HCC). [(18)F]-fluoroacetate ((18)F-FACE) is an [(18)F] fluorinated acetate, which is known to be converted into fatty acids, incorporated in membrane and is expected to be a promising oncologic PET tracer. The aim of this study was to evaluate the usefulness of (18)F-FACE as an oncologic PET tracer in preclinical study in healthy volunteers and in patients with liver tumors. METHODS: Twenty-four healthy volunteers (age 48.2 ± 12.9 years old; 15 male and 9 female) and ten patients with liver tumor (age 72.1 ± 7.0 years old; 6 male and 4 female) were included. We performed whole-body static PET/CT scan using (18)F-FACE (n = 34) and (18)F-FDG (n = 5 for volunteers, n = 8 for patients) on each day, respectively. Qualitative analysis and quantitative analysis of tumors (5 HCCs, 1 cholangiocellular carcinoma, 4 metastatic tumors from colon cancer and P-NET) were performed using SUVmax and tumor-to-normal liver ratio (TNR). RESULTS: In healthy volunteers, (18)F-FACE was metabolically stable in vivo and its biodistribution was almost similar to blood pool, basically uniformly independent of age and gender during PET scan time (up to 3 h). Normal physiological uptake of (18)F-FACE at each organ including liver (SUVmean 1.8 ± 0.2) was lower than that of blood pool (SUVmean 2.3 ± 0.3) at 1 h after injection. Chronic inflammatory uptake around femur of post-operative state of femoral osteotomy and faint uptake of benign hemangioma were observed in a case of healthy volunteer. (18)F-FACE (SUVmax 2.7 ± 0.6, TNR 1.5 ± 0.4) of liver tumors was significantly lower than those of (18)F-FDG uptake (6.5 ± 4.2, 2.6 ± 1.7, respectively). In qualitative analysis, (18)F-FDG was positive in 4 tumors (3 HCCs, 1 CCC) and negative in the other 6 tumors, while (18)F-FACE was also positive in 4 tumors which were the same tumors with positive (18)F-FDG uptake. CONCLUSIONS: Biodistribution of (18)F-FACE was appropriate for oncologic imaging. Tumor (18)F-FACE uptake was positive in four patients with HCC and CCC, but the uptake pattern was similar to (18)F-FDG. Further evaluation was needed.

Avaliação ultra-sonográfica de nódulos sideróticos esplênicos em pacientes esquistossomóticos com hipertensão portal / Ultrasonographic assessment of splenic siderotic nodules in schistosomal patients with portal hypertension", "_i": "en

OBJETIVO: Medir a sensibilidade e a reprodutibilidade da ultra-sonografia na detecção de nódulos sideróticos esplênicos em pacientes esquistossomóticos, tendo a ressonância magnética como padrão de referência. MATERIAIS E MÉTODOS: Na primeira fase do trabalho, 21 pacientes portadores de esquistossomose na forma hepatoesplênica com diagnóstico de nódulos sideróticos à ressonância magnética foram submetidos a avaliação ultra-sonográfica para a determinação da sensibilidade do método. Na segunda fase, com o objetivo de avaliar a reprodutibilidade da ultra-sonografia na detecção e na quantificação de nódulos sideróticos (A: 1-5 nódulos; B: 6-20 nódulos; C: mais de 20 nódulos), outros 30 pacientes esquistossomóticos foram submetidos a avaliação ultra-sonográfica de forma cega e independente por dois observadores. A reprodutibilidade foi medida por meio da concordância entre os observadores e do teste kappa. RESULTADOS: A sensibilidade da ultra-sonografia foi de 95,2 por cento (intervalo de confiança a 95 por cento [77,3 por cento; 99,2 por cento]). A concordância entre ultra-sonografia e ressonância magnética para a detecção de nódulos sideróticos foi de 96,7 por cento (intervalo de confiança a 95 por cento [82,8 por cento; 99,9 por cento]). Para a classificação dos nódulos conforme a sua quantificação, o índice kappa demonstrou concordância interobservador substancial (kappa = 0,67). CONCLUSÃO: A ultra-sonografia é um método que apresenta elevada sensibilidade e boa precisão para a avaliação de nódulos sideróticos esplênicos.

OBJECTIVE: To evaluate ultrasound sensitivity and reproducibility as compared with magnetic resonance imaging as the gold standard in the detection of splenic siderotic nodules in schistosomal patients. MATERIALS AND METHODS: Initially, 21 patients with hepatosplenic schistosomiasis and diagnosed with splenic siderotic nodules by magnetic resonance imaging were ultrasonographically evaluated for determining the method sensitivity. In a second phase, the method reproducibility in the detection and quantification of siderotic nodules (A: 1-5 nodules; B: 6-20 nodules; C: > 20 nodules) was evaluated in 30 patients who were submitted to ultrasonography blindly and independently assessed by two observers. Interobserver agreement was measured by kappa statistics. RESULTS: Ultrasound sensitivity was 95.2 percent (95 percent confidence interval [77.3 percent; 99.2 percent]). Intermethod agreement in the detection of siderotic nodules was 96.7 percent (95 percent confidence interval [82.8 percent; 99.9 percent]). For classification of nodules according to their quantification, the kappa test demonstrated a statistically significant interobserver agreement (kappa = 0.67). CONCLUSION: Ultrasonography is highly sensitive and accurate in the assessment of splenic siderotic nodules in schistosomal patients.